Description

The risk of fatal infection and immunosuppression induced complications is higher in patients in countries like India. Tacrolimus is used as an induction agent , by starting Tacrolimus induction 2 days prior to living donor kidney transplant for related cases. When compared with patients given standard induction therapies, patients with tacrolimus induction had very less incidence of infections 1 year post transplant. Though the risk of tacrolimus induced AKI was also seen in a few cases with Tacrolimus induced patients, when compared with the risk of infections and incidence of life threatening infections needing ICU, AKI incidence due to tacrolimus were less and reversible. We propose a networking session to discuss our experience and have an open session with experts from similar country zones and rest of the world to have their inputs and debate whether we need to consider lowering the induction immunosuppression for living donor kidney transplant patients? Tacrolimus is used as an induction agent , by starting Tacrolimus induction 2 days prior to living donor kidney transplant for related cases. When compared with patients given standard induction therapies, patients with tacrolimus induction had very less incidence of infections 1 year post transplant. Though the risk of tacrolimus induced AKI was also seen in a few cases with Tacrolimus induced patients, when compared with the risk of infections and incidence of life threatening infections needing ICU, AKI incidence due to tacrolimus were less and reversible. We propose a networking session to discuss our experience and have an open session with experts from similar country zones and rest of the world to have their inputs and debate whether we need to consider lowering the induction immunosuppression for living donor kidney transplant patients?